Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $90,070 | 44 | 74.2% |
| Unspecified | $18,886 | 21 | 15.6% |
| Acquisitions | $7,337 | 2 | 6.0% |
| Travel and Lodging | $2,333 | 9 | 1.9% |
| Food and Beverage | $1,655 | 25 | 1.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $601.62 | 2 | 0.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $500.00 | 1 | 0.4% |
| Education | $14.58 | 2 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $25,362 | 29 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $13,633 | 20 | $0 (2023) |
| GlaxoSmithKline, LLC. | $11,700 | 2 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $11,647 | 12 | $0 (2020) |
| EMD Serono, Inc. | $10,950 | 3 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $8,423 | 14 | $0 (2024) |
| Eli Lilly and Company | $8,030 | 3 | $0 (2018) |
| ABBVIE INC. | $7,337 | 2 | $0 (2024) |
| GENZYME CORPORATION | $7,275 | 3 | $0 (2022) |
| Amgen Inc. | $7,123 | 6 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,157 | 4 | ABBVIE INC. ($7,337) |
| 2023 | $3,778 | 1 | Regeneron Pharmaceuticals, Inc. ($3,778) |
| 2022 | $5,528 | 14 | Regeneron Pharmaceuticals, Inc. ($2,954) |
| 2021 | $23,907 | 16 | EMD Serono, Inc. ($10,950) |
| 2020 | $26,595 | 11 | GlaxoSmithKline, LLC. ($11,050) |
| 2019 | $9,929 | 11 | E.R. Squibb & Sons, L.L.C. ($6,723) |
| 2018 | $24,520 | 29 | Eli Lilly and Company ($7,480) |
| 2017 | $14,983 | 20 | Novartis Pharmaceuticals Corporation ($9,568) |
All Payment Transactions
106 individual payment records from CMS Open Payments — Page 5 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/14/2017 | Eli Lilly and Company | ALIMTA (Drug), CYRAMZA, PORTRAZZA | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 06/04/2017 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Travel and Lodging | In-kind items and services | $89.62 | General |
| Category: Oncology | ||||||
| 06/04/2017 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $88.87 | General |
| Category: Oncology | ||||||
| 06/02/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $74.30 | General |
| Category: Oncology | ||||||
| 06/02/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $72.05 | General |
| Category: Oncology | ||||||
| 06/02/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $2.58 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $9,878 | 16 |
| A PHASE 1B-2 DOSE ESCALATION AND COHORT EXPANSION STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF A NOVEL TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I KINASE INHIBITOR GALUNISERTIB ADMINISTERED IN COMBINATION WITH ANTI-PD-1 NIVOLUMAB IN ADVANCED REFRACTORY SOLID TUMORS PHASE 1B AND IN RECURRENT OR REFRACTORY NON-SMALL CELL LUNG CANCER, HEPATOCELLULAR CARCINOMA, OR GLIOBLASTOMA PHASE 2 | Eli Lilly and Company | $6,930 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,406 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $537.54 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $134.82 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 111 | 214 | $72,289 | $21,333 |
| 2022 | 3 | 92 | 164 | $57,065 | $15,818 |
| 2021 | 3 | 71 | 169 | $57,478 | $16,234 |
| 2020 | 3 | 73 | 149 | $53,368 | $13,151 |
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 60 | 141 | $48,504 | $14,823 | 30.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 29 | 51 | $13,005 | $3,694 | 28.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 22 | 22 | $10,780 | $2,816 | 26.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 44 | 100 | $34,400 | $9,559 | 27.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 27 | 27 | $13,230 | $3,876 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 21 | 37 | $9,435 | $2,383 | 25.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 39 | 122 | $41,968 | $12,326 | 29.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 15 | 15 | $7,350 | $2,026 | 27.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 17 | 32 | $8,160 | $1,882 | 23.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 38 | 112 | $38,528 | $9,391 | 24.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 23 | 23 | $11,270 | $2,938 | 26.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 12 | 14 | $3,570 | $820.95 | 23.0% |
About Dr. Scott Antonia, MD
Dr. Scott Antonia, MD is a Internal Medicine healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1669404091.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Antonia, MD has received a total of $121,397 in payments from pharmaceutical and medical device companies, with $12,157 received in 2024. These payments were reported across 106 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($90,070).
As a Medicare-enrolled provider, Antonia has provided services to 347 Medicare beneficiaries, totaling 696 services with total Medicare billing of $66,535. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Tampa, FL
- Active Since 07/07/2006
- Last Updated 02/05/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1669404091
Products in Payments
- LIBTAYO (Biological) $15,191
- OPDIVO (Biological) $11,559
- IMFINZI (Drug) $4,259
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $3,657
- SARCLISA (Biological) $1,962
- ALIMTA (Drug) $1,100
- KEYTRUDA (Biological) $959.31
- NIR178X (Drug) $672.36
- TECENTRIQ (Biological) $601.62
- PDR001 (Drug) $82.14
- LORBRENA (Drug) $12.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Tampa
Javier Pinilla-Ibarz, Md, MD
Internal Medicine — Payments: $1.9M
Alberto Chiappori, Md, MD
Internal Medicine — Payments: $617,120
Ricardo Restrepo-Jaramillo, M.d, M.D
Internal Medicine — Payments: $562,511
Dr. Sady Alpizar, Md, MD
Internal Medicine — Payments: $509,824
Jhanelle Gray, Md, MD
Internal Medicine — Payments: $273,892
Dr. Andrew Kuykendall, M.d, M.D
Internal Medicine — Payments: $273,357